Skip to main content
Premium Trial:

Request an Annual Quote

Gene Logic Reports Steep Increase in Revenues, Sightly Narrowed Net Loss

NEW YORK, April 23 (GenomeWeb News) - Gene Logic reported a steep increase in revenues and slightly narrowed losses for the first quarter today.


Revenues for the quarter climbed to $20.2 million, from $12.7 million during the same period last year. The company attributed most of this increase to revenues from Gene Logic Laboratories, formerly TherImmune Resaerch, which it acquired last April.


Research and development costs decreased to $0.4 million, from $0.6 million during the first quarter of 2003.


Gene Logic's net loss narrowed to $5.5 million, or $.18 per share, from $5.8 million, or $.21 per share, for the first quarter last year.


As of March 31, Gene Logic had $110.8 million in cash, cash equivalents, and marketable securities, of which $53.7 million were cash and cash equivalents.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.